4Q and Full Year 2025 Financial Results February 23, 2026 © Axsome Therapeutics, Inc. Forward looking statements & safe harbor Certain matters discussed in this presentation are "forward-looking statements" . The Company may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward- looking ...

Total 4Q and full year 2025 net product revenue of $196.0 million and $638.5 million, respectively,representing 65% and 66% year-over-year growth AUVELITY® 4Q and full year 2025 net product sales of $155.1 million and $507.1 million, respectively,representing 68% and 74% year-over-year growth SUNOSI® 4Q and full year 2025 net product revenue of $36.7 million and $124.8 million, respectively,representing 40% and 32% year-over-year growth SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $ ...

Core Insights - Axsome Therapeutics is gaining prominence in the biotech sector, outperforming broader equities over the past five years and showing potential for continued strong performance over the next decade [1][2] Company Overview - Axsome Therapeutics specializes in developing medicines for central nervous system conditions, with approved products like Auvelity for depression and Symbravo for migraines [4] - The company is also advancing AXS-12 for narcolepsy, which has completed phase 3 clinical trials, with regulatory submissions expected in Q4 [6] Market Opportunity - The market for Alzheimer's disease (AD) agitation, which affects over 5 million patients in the U.S., presents a significant commercial opportunity, especially as the aging population increases [5] - Auvelity is positioned to enter a growing market with high unmet needs and limited competition [5] Financial Potential - Axsome's late-stage pipeline has a peak sales potential exceeding $16 billion, while the current market cap stands at $9.3 billion [8] - The company enjoys a gross margin of 90.31% and has patent protection for its products until the 2040s, mitigating risks associated with patent cliffs [8]

The anticipated EPS of -$0.70 and revenue of $193.3 million for the quarter ending December 2025.Negative P/E ratio of -40.57 but potential growth indicated by revenue projections.Concerns over negative operating cash flow with an enterprise value to operating cash flow ratio of -91.91.Axsome Therapeutics, listed on NASDAQ:AXSM, is a biopharmaceutical company focused on developing therapies for central nervous system disorders. The company is set to release its quarterly earnings on February 23, 2026. Wall ...

Core Insights - Axsome Therapeutics, Inc. is set to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026, at 2:00 p.m. ET, highlighting its role in CNS disorder treatments [1] - The company focuses on developing differentiated products with novel mechanisms of action to improve patient outcomes in CNS conditions [3] Company Overview - Axsome Therapeutics is a biopharmaceutical company dedicated to addressing critical gaps in CNS care, with a portfolio that includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness, and migraine [3] - The company has multiple early and late-stage development programs targeting serious neurological and psychiatric conditions affecting over 150 million people in the U.S. [3] Investor Information - A live webcast of the upcoming presentation will be available on the company's website, with a replay accessible for approximately 30 days post-event [2]

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by A ...

Axsome Therapeutics (AXSM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 23, might help the stock move higher if these key numbers are better ...

Core Insights - Axsome Therapeutics has experienced a significant stock increase of approximately 75% over the past 12 months, outperforming the S&P 500, which rose by 15% during the same period [1] - The company is set to report its quarterly results on February 23, 2026, which will include numbers for the last three months of 2025 and full-year results [2] Financial Performance - In its most recent earnings report for the period ending September 30, 2025, Axsome's revenue increased by 63% year-over-year, totaling $171 million, while the net loss decreased from $64.6 million to $47.2 million [5] - Despite the strong earnings, the stock price did not see a significant increase following the report, rising less than 2% a week later [6] Regulatory Developments - A major catalyst for the stock occurred on December 31, 2025, when regulators granted priority review for the company's Alzheimer's drug, AXS-05, with a target action date of April 30, 2026, leading to a 23% jump in shares on the announcement day [6] Market Valuation - Axsome's market capitalization has reached approximately $9.4 billion, but the company remains unprofitable and trades at a price-to-sales multiple of 16, indicating a potentially expensive investment [7] - The company's growth stage suggests that regulatory news may have a more significant impact on share price than earnings results, as evidenced by the stock's reaction to the AXS-05 news [8]

Core Insights - Axsome Therapeutics has shown significant market performance over the past five years, driven by clinical and regulatory advancements, and is approaching large-cap status [1] - There remains potential for further investment in Axsome Therapeutics due to ongoing growth and new product developments [1] Group 1: Sales Growth - Axsome's revenue for the third quarter reached $171 million, reflecting a 63% increase compared to the same period last year [2] - The company's current product lineup includes Auvelity for depression, Sunosi for narcolepsy-related daytime sleepiness, and Symbravo for migraines, all contributing to strong sales growth [2][3] Group 2: Future Approvals - Axsome is pursuing new approvals and label expansions, including a new indication for Auvelity in treating Alzheimer's disease agitation, which has shown positive results in phase 3 studies and is under FDA consideration [4] - Sunosi has completed a phase 3 study for ADHD in adults, with plans for additional late-stage trials in related markets [5] Group 3: New Product Pipeline - The company is developing several other products, such as AXS-12 for cataplexy in narcolepsy and AXS-14 for fibromyalgia, which could significantly enhance sales potential [6] - The addressable market for Alzheimer's agitation is substantial, with over 5 million patients in the U.S. and currently only one FDA-approved treatment available [7]

Core Insights - Axsome Therapeutics Inc. (NASDAQ:AXSM) is recognized as a promising mid-cap stock by leading investors, with H.C. Wainwright raising its price target from $200 to $260 while maintaining a Buy rating [1] - The company reported interim unaudited financial results for Q4 2025, projecting total product revenue of approximately $196 million [1] Revenue Projections - Axsome anticipates overall product revenue of around $638.5 million for fiscal year 2025, representing a 66% increase compared to fiscal year 2024, surpassing H.C. Wainwright's estimate of $628.3 million [2] - The primary product, AUVELITY, is expected to generate net sales of about $155.1 million in Q4 and $507.1 million for the full year 2025, significantly exceeding the firm's annual sales estimate of $397 million [2] Performance of Other Products - Other products, such as SUNOSI, are also projected to perform well, with expected revenues of $36.7 million in Q4 and $124.8 million for the entire year [3] - Axsome Therapeutics focuses on developing novel therapies for central nervous system (CNS) disorders in the US [3]